A. Montero

Publications183
h-index29
Citations4,037
Highly Influential Citations140
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Hortobagyi
  • 1,367 Publications, 97,593 Citations
  • E. Winer
  • 972 Publications, 55,300 Citations
  • V. Bronte
  • 288 Publications, 27,447 Citations
  • H. Rugo
  • 673 Publications, 27,489 Citations
  • Publications
  • Influence
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Abnormal accumulation of myeloid-derived suppressor cells (MDSC) is an important mechanism of tumor immune evasion. Cyclophosphamide (CTX) has also been shown in non-tumor bearing animals to cause… Expand
  • 1,021
  • 35
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.
We recently demonstrated that human BM cells can be treated in vitro with defined growth factors to induce the rapid generation of myeloid-derived suppressor cells (MDSCs), hereafter defined as… Expand
  • 279
  • 16
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We… Expand
  • 122
  • 7
  • PDF
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review
Transcriptional silencing of tumor suppressor genes, associated with DNA methylation, is a common epigenetic event in hematologic malignancies. Although DNA hypermethylation of CpG islands is well… Expand
  • 71
  • 6
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Objective:nab-Paclitaxel has been shown to disrupt pancreatic cancer stroma and was effective in combination with gemcitabine in a phase I/II trial. This study was designed to determine the efficacy… Expand
  • 85
  • 5
  • PDF
Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer
It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum… Expand
  • 66
  • 5
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
The vulnerability of some cancer cells to oxidative signals is a therapeutic target for the rational design of new anticancer agents. In addition to their well characterized effects on cell division,… Expand
  • 147
  • 4
Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective
Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively… Expand
  • 198
  • 4
Molecular Profiling for Breast Cancer: A Comprehensive Review
In recent years advances in molecular biology have launched disruptive innovations in breast cancer diagnostics and therapeutics. The advent of genomics has revolutionized our understanding of breast… Expand
  • 109
  • 4
  • PDF
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
BackgroundDNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous… Expand
  • 57
  • 4